Mark Hopman Sells 1,258 Shares of Beta Bionics (NASDAQ:BBNX) Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mark Hopman sold 1,258 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $15.01, for a total transaction of $18,882.58. Following the completion of the transaction, the insider directly owned 129,354 shares in the company, valued at $1,941,603.54. This trade represents a 0.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Hopman also recently made the following trade(s):

• On Thursday, June 4th, Mark Hopman sold 275 shares of Beta Bionics stock. The stock was sold at an average price of $12.31, for a total value of $3,385.25.
• On Tuesday, June 2nd, Mark Hopman sold 5,329 shares of Beta Bionics stock. The shares were sold at an average price of $12.61, for a total value of $67,198.69.

Beta Bionics Price Performance

BBNX stock opened at $16.82 on Friday. Beta Bionics, Inc. has a 1 year low of $8.80 and a 1 year high of $32.71. The firm has a market capitalization of $749.53 million, a PE ratio of -11.14 and a beta of 3.40. The business has a 50 day simple moving average of $12.13 and a 200-day simple moving average of $15.58.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings data on Tuesday, April 21st. The company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. The firm had revenue of $27.63 million for the quarter. Beta Bionics had a negative return on equity of 23.00% and a negative net margin of 60.27%. On average, equities research analysts expect that Beta Bionics, Inc. will post -2.22 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Leerink Partners reduced their price target on Beta Bionics from $25.00 to $24.00 and set an “outperform” rating on the stock in a report on Wednesday, April 22nd. The Goldman Sachs Group dropped their price objective on shares of Beta Bionics from $19.00 to $17.00 and set a “buy” rating for the company in a report on Wednesday, May 27th. Weiss Ratings cut shares of Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, April 21st. Bank of America cut their price objective on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating for the company in a research report on Monday, May 18th. Finally, Truist Financial reduced their target price on shares of Beta Bionics from $25.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, April 15th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Beta Bionics presently has an average rating of “Moderate Buy” and a consensus target price of $19.70.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in BBNX. Summit Securities Group LLC acquired a new stake in Beta Bionics during the fourth quarter worth $52,000. Caitong International Asset Management Co. Ltd lifted its stake in shares of Beta Bionics by 1,075.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after purchasing an additional 1,818 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Beta Bionics by 203.6% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock valued at $47,000 after purchasing an additional 1,594 shares during the last quarter. Strs Ohio purchased a new position in shares of Beta Bionics during the 1st quarter worth $29,000. Finally, Ameritas Investment Partners Inc. grew its holdings in shares of Beta Bionics by 139.1% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 3,202 shares of the company’s stock worth $64,000 after purchasing an additional 1,863 shares during the period.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.